Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA supports CMS's ESA policy

FDA endorsed CMS's National Coverage Decision (NCD) on erythropoiesis-stimulating agents (ESAs) for cancer and related neoplastic conditions in a letter released Tuesday by

Read the full 238 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE